Telomir Pharmaceuticals (TELO) Competitors $1.37 +0.11 (+8.73%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$1.36 -0.01 (-1.02%) As of 09/11/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. ALTS, BTMD, CTOR, SXTC, NVCT, MCRB, LFVN, KYTX, MEIP, and BDTXShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include ALT5 Sigma (ALTS), biote (BTMD), Citius Oncology (CTOR), China SXT Pharmaceuticals (SXTC), Nuvectis Pharma (NVCT), Seres Therapeutics (MCRB), Lifevantage (LFVN), Kyverna Therapeutics (KYTX), MEI Pharma (MEIP), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors ALT5 Sigma biote Citius Oncology China SXT Pharmaceuticals Nuvectis Pharma Seres Therapeutics Lifevantage Kyverna Therapeutics MEI Pharma Black Diamond Therapeutics Telomir Pharmaceuticals (NASDAQ:TELO) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations. Do analysts recommend TELO or ALTS? Telomir Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 994.89%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in TELO or ALTS? 6.3% of ALT5 Sigma shares are owned by institutional investors. 4.9% of ALT5 Sigma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is TELO or ALTS more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. ALT5 Sigma's return on equity of -179.27% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -4,595.08% -1,750.91% ALT5 Sigma -74.89%-179.27%-16.28% Which has more volatility & risk, TELO or ALTS? Telomir Pharmaceuticals has a beta of -0.73, suggesting that its share price is 173% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Does the media prefer TELO or ALTS? In the previous week, ALT5 Sigma had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 8 mentions for ALT5 Sigma and 6 mentions for Telomir Pharmaceuticals. ALT5 Sigma's average media sentiment score of 0.47 beat Telomir Pharmaceuticals' score of -0.18 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral ALT5 Sigma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, TELO or ALTS? ALT5 Sigma has higher revenue and earnings than Telomir Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.54-2.54ALT5 Sigma$12.53M6.85-$6.24MN/AN/A SummaryALT5 Sigma beats Telomir Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.67M$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E Ratio-2.5423.7675.3726.21Price / SalesN/A564.68471.1491.59Price / CashN/A169.2537.0859.91Price / Book68.505.3911.906.28Net Income-$16.53M$32.95M$3.29B$270.85M7 Day Performance10.48%2.61%1.49%3.58%1 Month Performance-11.61%9.87%7.72%6.67%1 Year Performance-76.94%1.49%59.32%27.73% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.0336 of 5 stars$1.37+8.7%$15.00+994.9%-76.9%$40.67MN/A-2.541Short Interest ↑ALTSALT5 Sigma0.2196 of 5 stars$5.58-29.2%N/A+71.1%$170.28M$12.53M0.00170Short Interest ↑High Trading VolumeBTMDbiote3.035 of 5 stars$3.43-0.3%$6.00+74.9%-43.6%$170.07M$197.19M3.81194Positive NewsCTORCitius Oncology1.8205 of 5 stars$2.01-7.4%$3.00+49.3%+11.8%$170.06MN/A0.00N/ASXTCChina SXT Pharmaceuticals0.9306 of 5 stars$1.42-2.7%N/A-65.3%$169.40M$1.74M0.0090Short Interest ↓NVCTNuvectis Pharma3.2805 of 5 stars$6.38-2.7%$15.33+140.3%+1.1%$167MN/A-5.458MCRBSeres Therapeutics3.1343 of 5 stars$19.52+3.1%$73.67+277.4%-16.3%$165.81M$126.32M-4.24330LFVNLifevantage4.0353 of 5 stars$13.55+3.4%$30.50+125.1%+24.5%$164.90M$200.16M19.64260High Trading VolumeKYTXKyverna Therapeutics3.3588 of 5 stars$3.59-3.2%$16.60+362.4%-40.6%$160.44M$7.03M-0.9896MEIPMEI Pharma1.4986 of 5 stars$4.85-0.2%N/A+5.6%$159.59MN/A-1.02100Positive NewsUpcoming EarningsGap DownBDTXBlack Diamond Therapeutics3.5579 of 5 stars$2.80+1.8%$12.40+342.9%-45.0%$156.57MN/A12.1790Positive News Related Companies and Tools Related Companies ALT5 Sigma Alternatives biote Alternatives Citius Oncology Alternatives China SXT Pharmaceuticals Alternatives Nuvectis Pharma Alternatives Seres Therapeutics Alternatives Lifevantage Alternatives Kyverna Therapeutics Alternatives MEI Pharma Alternatives Black Diamond Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts